Tango Therapeutics, Inc. (TNGX) |
|
7.41 -0.04 (-0.54%)
|
11-28 10:44 |
|
Open: |
7.43 |
Pre. Close: |
7.45 |
|
High:
|
7.65 |
Low:
|
7.41 |
|
Volume:
|
126,757 |
Market Cap:
|
653(M) |
|
|
|
Technical analysis |
as of: 2022-11-28 10:22:28 AM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 9.22  One year: 9.99 |
| Support: |
Support1: 6.84 Support2: 5.69 |
| Resistance: |
Resistance1: 7.9 Resistance2: 8.55 |
| Pivot: |
7.71 |
| Moving Average: |
MA(5): 7.62  MA(20): 7.7
MA(100): 5.22 MA(250): 6.7 |
| MACD: |
MACD(12,26): 0.3 Signal(9): 0.4 |
| Stochastic oscillator: |
%K(14,3): 40.2 %D(3): 43.7 |
| RSI: |
RSI(14): 57.5 |
| 52-week: |
High: 11.72 Low: 3.18 |
| Average Vol(K): |
3-Month: 218 (K) 10-Days: 159 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ TNGX ] has closed above bottom band by 42.9%. Bollinger Bands are 48.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 6 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
7.75 - 7.81 |
7.81 - 7.85 |
|
Low:
|
7.25 - 7.32 |
7.32 - 7.38 |
|
Close:
|
7.35 - 7.45 |
7.45 - 7.52 |
|
Company Description |
|
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts. |
Headline News |
Fri, 18 Nov 2022
More than two Tango in PRMT5 space; Amgen, Mirati in play - BioWorld Online
Wed, 16 Nov 2022
Wedbush Increases Tango Therapeutics (NASDAQ:TNGX) Price Target to $21.00 - MarketBeat
Mon, 14 Nov 2022
Tango Therapeutics: Behind The Recent Momentum (NASDAQ:TNGX) - Seeking Alpha
Thu, 10 Nov 2022
Tango Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Highlights - Yahoo Finance
Mon, 07 Nov 2022
Tango Therapeutics to Participate in Upcoming Investor Conferences - Tango Therapeutics (NASDAQ:TNGX) - Benzinga
Tue, 18 Oct 2022
Is it Time to Dump Tango Therapeutics Inc (TNGX) Stock After it Has Risen 57.93% in a Week? - InvestorsObserver
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
88 (M) |
| Shares Float |
43 (M) |
|
% Held by Insiders
|
15.2 (%) |
|
% Held by Institutions
|
78 (%) |
|
Shares Short
|
1,250 (K) |
|
Shares Short P.Month
|
1,060 (K) |
Stock Financials |
|
EPS
|
-0.98 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
3.09 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-424.2 |
|
Return on Assets (ttm)
|
-12.9 |
|
Return on Equity (ttm)
|
-31.7 |
|
Qtrly Rev. Growth
|
2 |
|
Gross Profit (p.s.)
|
-0.47 |
|
Sales Per Share
|
0.27 |
|
EBITDA (p.s.)
|
-1.15 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-98 (M) |
|
Levered Free Cash Flow
|
-44 (M) |
Stock Valuations |
|
PE Ratio
|
-7.89 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
2.46 |
|
Price to Sales
|
27.92 |
|
Price to Cash Flow
|
-6.91 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
